Brenda Adamovich, DO
Neurology · Wheeling, WVNPI 1679784003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $701 and has fallen 96.0% since, to $28 in 2024.
Across 97 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$312
- AbbVie$247
- Tanabe Pharma America, Inc.$132
- Lilly USA, LLC$117
- Sanofi$94
- UCB, Inc.$88
- plus $794 from 19 others
What the payments were for
- Speaking & faculty fees$493%
- Food & beverage$1,69495%
- Education$422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $312 |
| AbbVie(2 entities) | 11 | $247 |
| Tanabe Pharma America, Inc. | 5 | $132 |
| Lilly USA, LLC | 7 | $117 |
| Sanofi | 5 | $94 |
| UCB, Inc. | 4 | $88 |
| Biogen | 4 | $80 |
| Amneal Pharmaceuticals LLC | 5 | $77 |
| Amgen | 3 | $68 |
| Genentech USA, Inc. | 3 | $65 |
| EMD Serono, Inc. | 3 | $50 |
| Acorda Therapeutics, Inc | 3 | $49 |
| Pfizer | 2 | $47 |
| Argenx US, Inc. | 2 | $46 |
| Lundbeck LLC | 2 | $45 |
| AstraZeneca | 2 | $43 |
| Assertio Therapeutics, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Adamas Pharmaceuticals, Inc. | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Banner Life Sciences, LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
How this compares
$1,785 in reported general payments places this provider in the 55th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 57 | $265,923 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $104,447 |
| Nurtec OdtRimegepant Sulfate | 44 | $63,557 |
| EliquisApixaban | 82 | $55,982 |
| Aimovig AutoinjectorErenumab-Aooe | 54 | $52,184 |
| RytaryCarbidopa/Levodopa | 13 | $14,518 |
| Memantine Hcl | 548 | $13,217 |
| BotoxOnabotulinumtoxina | 12 | $11,174 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 342 | $10,799 |
| Levetiracetam | 394 | $9,417 |
| Entacapone | 53 | $8,850 |
| Gabapentin | 699 | $8,564 |
| Carbamazepine ErCarbamazepine | 90 | $8,532 |
| Rivastigmine | 52 | $8,513 |
| Lacosamide | 63 | $8,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $28 | $265,92357 claims |
| PfizerNurtec Odt, Eliquis | $47 | $119,539126 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $77 | $16,25239 claims |
| AbbVieBotox | $247 | $11,17412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 93 neurology providers in West Virginia.
Other neurology in Wheeling
- Stephen TimmsWheeling$4K
- Rebecca BarnesWheeling$3K
- John TellersWheeling$583
- Barry VaughtCrab Orchard$1.4M
- Paul FergusonHuntington$649K
- Umer NajibMorgantown$246K
- Muhammed Nasher-AlneamCharleston$73K
- Robert LewisHurricane$73K
- Lauren SeebergerCharleston$72K
- Cheryl SmithMorgantown$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.